New diagnoses belong to the field of suspected diseases and blood tumors, clinical performance is complex and often involves multiple systems. Early identification and standardized clinical care are essential for improving prognosis. The diagnosis of this disease requires a combination of clinical performance, imaging inspection, laboratory testing and pathological evaluation.
The platform can assist in matching a team of authoritative experts at home and abroad to provide accurate diagnosis and treatment. Treatment and management of new diagnoses of immune platelet reduction require individualized development, usually including multidimensional management of prognosis, including drug therapy, rehabilitation, regular follow-up, etc. In recent years, with the development of treatment-oriented, immune-regulatory therapy and precision medicine, many previously difficult-to-treat blood tumour diseases have been significantly improved.
Treatment needs to be closely monitored for efficacy and adverse reactions, adapted to the timely schedule according to changes in the disease. Multidisciplinary collaboration (MDT) is particularly important for the comprehensive management of new diagnoses of immune platelet reduction. 2.
Visiting China: arranging face-to-face treatment with authoritative experts, developing individualized treatment programs; 3. Full-service: providing one-stop services such as medical translation, medical care, accommodation arrangements; 4. Long-term follow-up: establishing a chronic disease management archive, continuous monitoring of disease changes and treatment effects.